Specifically, we conducted the current NMA to evaluate the potentially different risk of colorectal tumors related to GLP-1 receptor agonists and SGLT2 inhibitors prescription in subjects without baseline colorectal tumors. Here, SLC5A2 is linked to colorectal neoplasm.